926922-29-4Relevant articles and documents
Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
Wang, Yihan,Shakespeare, William C.,Huang, Wei-Sheng,Sundaramoorthi, Raji,Lentini, Scott,Das, Sasmita,Liu, Shuangying,Banda, Geeta,Wen, David,Zhu, Xiaotian,Xu, Qihong,Keats, Jeffrey,Wang, Frank,Wardwell, Scott,Ning, Yaoyu,Snodgrass, Joseph T.,Broudy, Mark I.,Russian, Karin,Dalgarno, David,Clackson, Tim,Sawyer, Tomi K.
scheme or table, p. 4907 - 4912 (2009/05/30)
Novel N9-arenethenyl purines, optimized potent dual Src/Abl tyrosine kinase inhibitors, are described. The key structural feature is a trans vinyl linkage at N9 on the purine core which projects hydrophobic substituents into the sele